Lecanemab: A Breakthrough in Alzheimer's Treatment and Therapeutics

A progressive neurodegenerative disorder Alzheimer’s disease is characterised by memory loss and cognitive decline which primarily affect the elderly person. There have been few disease-modifying effects from traditional treatment options, which have mostly been symptomatic. By delaying the pathological progression of early Alzheimer's disease, lecanemab, a monoclonal antibody that targets soluble amyloid-beta protofibrils, has brought about a novel therapeutic approach. The development, mechanism of action, adverse effects, synthesis, clinical trial data, and marketing insights of lecanemab are all examined in this article. Early-stage patients' cognitive slowing has shown statistically significant results in the pivotal CLARITY-AD trial. However, there are also significant side effects linked to lecanemab use, including neuropsychiatric symptoms, infusion-related reactions, and amyloid-related imaging abnormalities (ARIA). Careful patient monitoring is required because post-marketing data, such as pharmacovigilance analysis from the FDA Adverse Event Reporting System (FAERS), highlights uncommon but serious events, including deaths. The article also covers future directions in Alzheimer's therapy, regulatory milestones, and formulation strategies. Lecanemab, a first-generation disease-modifying drug in this class, exemplifies both the advancement of science and the difficulty of converting laboratory results into clinical use.